Clear Harbor Asset Management LLC bought a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 730 shares of the company’s stock, valued at approximately $44,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA bought a new stake in shares of Crispr Therapeutics during the fourth quarter worth $26,000. State Street Corp increased its holdings in Crispr Therapeutics by 2.1% in the third quarter. State Street Corp now owns 37,103 shares of the company’s stock valued at $1,521,000 after purchasing an additional 758 shares during the last quarter. Webster Bank N. A. bought a new stake in Crispr Therapeutics in the fourth quarter valued at about $26,000. Millennium Management LLC bought a new stake in Crispr Therapeutics in the third quarter valued at about $4,366,000. Finally, Exchange Traded Concepts LLC bought a new stake in Crispr Therapeutics in the fourth quarter valued at about $54,000. Institutional investors own 49.84% of the company’s stock.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold 48,618 shares of company stock valued at $3,230,760 over the last 90 days. Corporate insiders own 21.40% of the company’s stock.

CRSP has been the subject of a number of recent analyst reports. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Chardan Capital reiterated a “buy” rating on shares of Crispr Therapeutics in a report on Thursday. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Goldman Sachs Group upped their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Finally, Canaccord Genuity upped their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a report on Wednesday, November 20th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $75.95.

Shares of Crispr Therapeutics stock opened at $51.95 on Friday. Crispr Therapeutics AG has a 1 year low of $29.34 and a 1 year high of $74.00. The business has a 50-day moving average of $61.06 and a two-hundred day moving average of $52.69. The company has a market capitalization of $2.87 billion, a P/E ratio of -112.93 and a beta of 3.20. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link